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syndrome (ACS) are also risk factors for bleeding, with patients often at high-risk of both 
outcomes. We aimed to define the clinical outcomes and provision of guideline-
recommended care in ACS management for different combinations of ischemic and bleeding 
risk defined using a combined GRACE and CRUSADE score. 
Methods:  A retrospective observational analysis of a national ACS database was performed 
for patients with ACS admitted to three tertiary centres from January 2010 to March 2016. 
Patients were stratified into 9 groups based on possible CRUSADE-GRACE risk 
combinations. Multiple logistic regression was used to estimate adjusted odds ratios (ORs 
[95% CI]) for outcomes (in-hospital net adverse cardiac events (NACE), in-hospital all-
cause mortality, 30-day mortality and treatment strategy). 
Results: A total of 17,701 patients were included in the analysis. We observed a graded risk 
of mortality and adverse events in the high-risk GRACE strata (Groups 3, 6 and 9). Almost a 
third of patients with ACS were at a ‘dual high-risk’ (Group 9, 32%) and were 
independently associated with higher in-hospital NACE (composite of cardiac mortality, all-
cause bleeding and re-infarction): aOR 6.33 [3.55, 11.29], all-cause mortality: aOR 14.17 
[5.27, 38.1],  all-cause bleeding: aOR 4.82 [1.96, 11.86], and 30-day mortality: aOR 10.79 
[5.33, 21.81]. This group was also the least likely to be offered coronary angiography (aOR 
0.24 [0.20, 0.29]) and dual anti-platelet therapy (aOR 0.26 [0.20, 0.34]).   
Conclusions: One in five patients presenting with an ACS are high ischemic and high 
bleeding risk, and these patients are more likely to experience poor clinical outcomes and 

















Acute coronary syndromes (ACS) are an important cause of morbidity and mortality 
worldwide. Current guidelines recommend early management with potent antiplatelet agents 
and an early invasive coronary intervention strategy for both non-ST elevation myocardial 
infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI).[1, 2] [3] The 
mainstay of pharmacologic treatment for ACS is the use of potent antithrombotic therapy to 
minimize the risk for further ischemic events, which comes at an expense of an increased risk 
of bleeding complications that are associated with high rates of morbidity and mortality.[4-7] 
 Patients presenting with acute coronary syndromes are a heterogeneous population, 
with often significant overlap of risk factors that are associated with both future ischemic and 
major bleeding events. Therefore, managing patients with an ACS is a balance of reducing 
the risk of future ischemic events whilst minimizing the risk of bleeding complications. Risk 
stratification of ACS patients for likelihood of future ischemic and mortality events is 
undertaken using a variety of risk scores including the Global Registry of Acute Cardiac 
Events (GRACE) score, that is recommended to guide an invasive treatment strategy[1, 2, 8, 
9] and was initially validated to predict in-hospital and 6-month mortality in acute coronary 
syndromes[10]. Several parameters comprising the GRACE score are also elements of the 
‘Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with 
Early implementation of the ACC/AHA guidelines’ (CRUSADE) bleeding score[11], which 
predicts the baseline risk of major in-hospital bleeding in patients with NSTEMI. 
 Given the shared risk factor profile in the future risk ischemic and bleeding events, 
patients presenting with ACS are made up of groups of patients with different balances in the 
risk of ischemic and bleeding events. Whilst previous studies have investigated outcomes 
associated with different strata of ischemic and bleeding risk in ACS separately[12-16], they 















what influence these combinations of risk have on treatment strategies and clinical outcomes 
in patients presenting with ACS. 
The objective of this study was to examine the clinical characteristics of different 
combinations of ischemic and bleeding risk in an unselected cohort of ACS patients from the 
Myocardial Infarction National Audit Project (MINAP) registry and to define their clinical 




The Myocardial Ischemia National Audit Project (MINAP) collects prospective data 
on the management of ACS in the UK. Each centre is responsible for data entry into MINAP, 
based on agreed definitions and options for each variable. This study had access to data from 
three large tertiary centres, namely, the Freeman Hospital (Newcastle-upon-Tyne, England), 
the Royal Stoke Hospital (Stoke-on-Trent, England) and the University Hospital of Wales 
(Cardiff, Wales).[17] The dataset includes variables detailing patient characteristics, 
emergency response/admission dates, processes of care and clinical outcomes within hospital 
discharge. Long-term mortality tracking was available from the Office for National Statistics 
for English patients and the Welsh Demographic Service for Welsh patients. 
 
Study Design and Population 
We performed a retrospective analysis of all patients with a confirmed discharge 
diagnosis of acute coronary syndrome, including STEMI, NSTEMI and unstable angina 
(UA). All cases with an ‘undetermined’ or alternative diagnosis coded on discharge were 
excluded. A flow chart of the study exclusions is presented in Supplementary Figure 1. Data 















CRUSADE scores using the previously published variables and coefficients.[10, 11] We 
performed multiple imputation analysis for all missing variables, which generated ten 
imputed datasets. All analyses were performed in each imputed dataset separately and then 
pooled using Rubin’s Rules.[18] The imputation models included the majority of variables in 
the MINAP dataset and included each of the outcomes considered in this study. Patients with 
missing outcome variables were excluded from the analysis of that outcome only (i.e. we did 
not impute outcomes, but rather used the raw values). Multiple imputation has demonstrated 
minimal bias in previous publications.[19, 20] The frequencies of missing data for all 
variables prior to multiple imputation are listed in Supplementary Table 1. Data on ethnicity 
was not available from one of the contributing centres (Cardiff, Wales) and, therefore, was 
excluded from univariate analysis.  
GRACE score was used to stratify patients in to three categories according to 6-month 
mortality score: low (<89), intermediate (89-118) and high (>118). CRUSADE score 
stratifies patient into 5 categories according to bleeding risk: very low (≤20), low (21-30), 
moderate (31-40), high (41-50) and very high (>50).  
For the purpose of combined GRACE and CRUSADE analysis, we reclassified the 
CRUSADE groups in to three categories by merging ‘Very Low-’ and ‘Low-’ risk groups 
into a ‘Low’ risk category and ‘High-’ and ‘Very High-’ risk groups into a ‘High’- risk 
category to allow a sufficient sample size in each combined risk group for analysis. Patients 
were subsequently grouped in to 9 risk profiles as a representation of all the possible 
permutations of combined CRUSADE and GRACE risk groups (key to all groups in Figure 
1).  
The primary outcome measures were in-hospital net acute cardiovascular events 
(NACE), in-hospital all-cause mortality, in-hospital all-cause bleeding and 30-day mortality.  















and re-infarction. All-cause bleeding was defined as any clinically evident bleeding or drop 
in haemoglobin as coded in the MINAP dataset (any bleeding with fall in Hb of <30g/dL, 30-
50g/dL or >50g/dL, ‘intracranial bleeding’ and ‘retroperitoneal haemorrhage’). The 
secondary outcome was the utilization of guideline-recommended therapy, measured by the 
rate of receipt of coronary angiography and dual antiplatelet therapy (DAPT).  
Statistical Analysis 
Statistical analysis was performed using SPSS version 24 (IBM Corp, Armonk, NY). 
Continuous variables were presented as means with standard deviation (SD) and compared 
using ANOVA.  Categorical variables were presented as frequencies and analysed using the 
chi-squared (X
2
) test, or a Fisher’s exact test whenever the frequency of an event was less 
than 5. Patients with missing endpoint variables were excluded from the analysis of that 
endpoint. 
Multiple logistic regression was used to investigate association between the combined 
CRUSADE-GRACE risk groups and clinical outcomes adjusting for the following variables: 
previous percutaneous coronary intervention (PCI), previous acute myocardial infarction 
(AMI), previous coronary artery bypass graft (CABG), hypertension, hypercholesterolemia, 
smoking status, body mass index (BMI) and admitting consultant (Cardiologist vs. General 
physician). Any covariates that were used to calculate the CRUSADE and/or GRACE scores 
(i.e. age, sex, renal function, peripheral vascular disease, cardiac arrest on admission, diabetes 
mellitus, blood pressure, heart rate, haematocrit level, elevated troponin level, Killip Class 
and ST-segment deviation) were not adjusted for, to avoid collinearity and multiple 
adjustment. All odds ratios (ORs) are adjusted and expressed as aOR [95% confidence 
interval], unless otherwise stated.  
A ROC analysis was performed to evaluate the performance of CRUSADE and 















bleeding and 30-day mortality). Logistic regression was conducted to generate predicted 
probabilities for the risk categories of either score.  
 
Results 
A total of 17,701 patients with a diagnosis of ACS (STEMI, NSTEMI and UA) were 
admitted to the three contributing centres between January 2010 and March 2016. The mean 
age of the study population was 65.9±13.1 years, with 70.8% (n=12530) males and 50.8% 
(n=9044) with a STEMI diagnosis. Patients' baseline characteristics are presented according 
to the nine CRUSADE-GRACE group combinations in Table 1, and according to separate 
GRACE and CRUSADE groups in Supplementary Tables 3 and 4, respectively. A 
distribution of the cohort by each contributing centre is also available in the supplementary 
material (Supplementary Table 2). Several variables are common to both GRACE and 
CRUSADE scores and there was a positive correlation between both scores, although this 
was relatively modest (Pearson’s coefficient: r=0.411, p<0.001). Low GRACE–Low 
CRUSADE group comprised 5.5% (n=973) of the population whilst High GRACE–High 
CRUSADE group comprised 32.0% (n=5671) of population.  
Several key differences in demographics and clinical characteristics were observed 
between the CRUSADE-GRACE group combinations (p-value is for trend). Low GRACE 
strata included the youngest patients and the lowest prevalence of Caucasians, chronic renal 
failure and peripheral vascular disease but also the highest prevalence of previous PCI; Group 
1 (Low CRUSADE – Low GRACE), Group 4 (Moderate CRUSADE – Low GRACE) and 
Group 7 (High CRUSADE - Low GRACE)  while the high-risk CRUSADE strata were less 
likely to be men; Group 7 (High CRUSADE - Low GRACE), Group 8 (High CRUSADE-
Intermediate GRACE) and Group 9 (High CRUSADE-High GRACE) (p<0.001 for all).  















dual high-ischemic high-bleeding risk patients (Group 9, High CRUSADE-High GRACE) 
were significantly older (71.9±11.9 vs. 51.8±9.6 years,), less likely to be males (62.7% vs. 
80.2%) and more multimorbid with a higher prevalence of cardiovascular risk factors such as 
previous angina (27.0% vs. 22.1%), previous acute AMI (25.3% vs. 19.3%), previous CABG 
(6.7% vs. 3.4%), hypertension (62.7% vs. 44.9%), previous PVD (8.6% vs. 1.3%), previous 
cerebrovascular disease (10.8% vs. 2.8%), asthma/COPD (18.9% vs. 12.5%), chronic renal 
failure (10.2% vs. 0.1%) and heart failure (6.1% vs. 0.6%) (Table 1, p<0.001 for all).  
NACE and Mortality 
The rates of in-hospital NACE and in-hospital mortality are listed according to 
CRUSADE-GRACE risk combinations in Table 2 and according to individual CRUSADE 
and GRACE categories in Supplementary Tables 5 and 6, respectively.  
Overall rates of in-hospital NACE, in-hospital all-cause mortality and 30-day 
mortality were 5.5% (n=974), 3.7% (n=684) and 4.3% (n=761) respectively. An incremental 
risk of all three events was observed in the high-risk GRACE strata, increasing as the 
CRUSADE risk component of the groups increased; Group 3 (Low CRUSADE – High 
GRACE), Group 6 (Moderate CRUSADE- High GRACE) and Group 9 (High CRUSADE – 
High GRACE) (Figures 2a and 2b). The frequency of adverse events in Groups 3, 6 and 9, 
respectively were: 3.1%, 5.9% and 10.9% for in-hospital NACE; 1.2%, 3.9% and 8.8% for 
in-hospital all-cause mortality; and 2.8%, 5.0% and 8.2% for 30-day mortality. There was a 
notable difference in outcomes between the highest and lowest risk groups (Group 9 vs. 
Group 1, respectively) for in-hospital NACE (10.9% vs. 1.1%, p<0.001), in hospital all-cause 
mortality (8.8% vs. 0.1%, p<0.001) and 30-day mortality (8.2% vs. 0.9%, p<0.001).  
An overview of the independent associations between different GRACE-CRUSADE 
categories and in-hospital NACE and all-cause mortality, and 30-day mortality is shown in 















NACE, in-hospital all-cause mortality and 30-day mortality amongst the 9 groups. However, 
the dual high-risk group (Group 9) was the strongest predictor of adverse events (in-hospital 
NACE: aOR 6.33 [3.55, 11.29], in-hospital all-cause mortality: aOR 14.17 [5.27, 38.1] and 
30-day mortality: aOR 10.79 [5.33, 21.81], p<0.001 all).  
Interestingly, the CRUSADE score was superior to the GRACE score in predicting in-
hospital NACE (AUC: 0.686 [0.670, 0.703] vs. 0.641 [0.626, 0.656]), in-hospital all-cause 
mortality (AUC: 0.738 [0.721, 0.755] vs. 0.664 [0.647, 0.680]) and 30-day mortality (AUC: 
0.659 [0.639, 0.678] vs. 0.640 [0.623, 0.656]) (Supplementary Figures 2a, 2b and 2d, 
respectively, p<0.001 for all).  
 
Bleeding 
The overall rate of in-hospital all-cause bleeding was 1.5% (n=266) (Table 2).  The 
majority of in-hospital all-cause bleeding events occurred in the ‘High-risk’ and ‘Very High-
risk’ CRUSADE groups (Supplementary Table 5) and ‘High-risk’ GRACE group 
(Supplementary Table 6). Amongst the combined CRUSADE-GRACE risk groups, the 
highest incidence of bleeding was observed in the ‘dual high-risk’ group (Group 9; 2.4%), 
followed by Group 6 (Moderate CRUSADE-High GRACE; 1.9%) and Group 9 (High 
CRUSADE-High GRACE; 1.1%) (Figure 2a). There was no significant difference in the 
rates of TIMI major bleeding between combined risk groups (Table 2, p=0.46).  
In multivariate analysis, only Groups 6 (Moderate CRUSADE-High GRACE) and 9 
(High CRUSADE-High GRACE) were significantly associated with a four to five-fold 
increase in odds of in-hospital all-cause bleeding (aOR 4.05 [1.60, 10.21] and aOR 4.82 
[1.96, 11.86], p≤0.001 for both) (Table 2b). A ROC analysis demonstrated superiority of 
CRUSADE over GRACE as predictor of in-hospital bleeding (AUC: 0.623 [0.589, 0.657] vs. 

















Coronary angiography was performed in the majority (72.3%) of the study cohort 
(Table 2). However, patients in the ‘High- and Very High-’ CRUSADE risk categories and 
those with a ‘High’-risk GRACE risk were significantly less likely to undergo coronary 
angiography compared to the corresponding low-risk categories of the same score 
(Supplementary Tables 5 and 6, respectively, p<0.001 for both trends). Within the 
CRUSADE-GRACE group combinations, the highest risk groups had the lowest proportions 
of patients receiving coronary angiography compared to all other groups (Group 9: 62% and 
Group 8: 69.7%) (Table 2, Figure 2c). Multivariable regression analysis identified 
membership of these two groups as independently associated with reduced odds of coronary 
angiography; Group 9: aOR 0.24 [0.20, 0.29] and Group 8: aOR 0.39 [0.31, 0.48], p<0.001 
for both) (Table 2b).   
The overall rate of discharge with DAPT after ACS was 84.3%. Within the individual 
risk groups, ‘High’-risk GRACE and ‘Very High’-risk CRUSADE groups were notably less 
likely to receive DAPT on discharge (80.5% and 72.9% respectively, p<0.001 for both 
trends). A similar trend was observed in the CRUSADE-GRACE combined groups, where 
Group 9 was significantly less likely to receive DAPT (n=74.6%, aOR 0.26 [0.20, 0.34], 
p<0.001) (Figure 2c) and more likely to be prescribed aspirin as a single antiplatelet agent 
(5.6%, crude OR 2.00 [1.60-2.85], p<0.001) on discharge.  
 
Sensitivity Analysis 
 A sensitivity analysis was performed to assess the difference in outcomes between 
Non-ST Elevation ACS (NSTEA-ACS) and STEMI patients. Patients presenting with STEMI 















mortality (5.2% vs. 2.2%), in-hospital all-cause bleeding (1.7% vs. 1.3%) and 30-day 
mortality (10% vs. 6.3%) compared to those presenting with NSTE-ACS (Supplementary 
Tables 7a and 7b, p<0.001 for all). However, the trend of outcomes in the combined 
CRUSADE-GRACE risk groups was similar in both STEMI and NSTE-ACS subgroups to 
that of the combined ACS cohort, with the highest rates of NACE, in-hospital all-cause 
mortality, in-hospital all-cause bleeding and 30-day mortality observed in the high-GRACE 
strata; Groups 3, 6 and 9.   
 
Discussion 
Patients presenting with acute coronary syndromes have a large overlap in the risk 
factor profiles that predict both future ischemic and major bleeding events. Our study 
suggests that one in three patients admitted with an acute coronary syndrome are at high risk 
of both bleeding and ischemic events and represent a high-risk group with adverse clinical 
outcomes, even after adjustment for their adverse baseline risk factor profile. We observe a 
lack of adherence to guideline-based therapy in this high-risk group, who were less likely to 
receive both invasive angiography and dual antiplatelet therapy. Balancing the ischemic 
benefits of revascularization and antiplatelet therapy against the bleeding risk presents a 
therapeutic dilemma in such patients, who by far have the most to gain from these therapeutic 
strategies.  
Risk assessment of future ischemia and bleeding, using the GRACE (Class I, Level 
A) and CRUSADE (Class IIb, Level B) scores respectively, is recommended by current 
guidelines to guide decision on treatment strategies, and is considered an essential quality 
indicator. [1, 2, 9] Yan et al. demonstrated the superiority of validated scoring systems in 
identifying high-risk patients that have been otherwise misclassified by physicians as of 















mortality in patients with NSTEMI, and is an indication for early coronary 
revascularization.[21] However, the inherent risk of bleeding from commitment to a certain 
duration of dual antiplatelet therapy remains a concern for clinicians hence reluctance to 
undertake coronary intervention in patients with dual high bleeding and ischaemic risk. 
Although the CRUSADE score reliably predicts in-hospital bleeding, the risk of bleeding is 
not confined to hospitalization.[22] A recent meta-analysis concluded that bleeding after 
percutaneous coronary intervention independently increases the risk of major acute 
cardiovascular events (MACE) and mortality by approximately three-fold at 1 year from the 
time of event.[5]  
To the best of our knowledge, this is the largest study to investigate both outcomes of 
patients of all ACS subtypes, based on their combined bleeding and ischemic risk profile, and 
evaluate the quality of their management against the latest guidelines. Paiva et al. studied the 
outcomes of 566 patients with NSTEMI over a mean period of 21 months post-discharge. In 
their single centre observational analysis, they reported significantly worse in-hospital 
mortality, bleeding and follow up mortality in the highest bleeding-ischemic risk group when 
compared with all other risk groups, which correlates with our study findings.[23].  
 The inverse relationship between patient risk and adherence to guideline-based 
management has been previously observed in several studies.[13, 24, 25] In an analysis of 
more than 71000 patients with NSTEMI diagnosis from the NCDR ACTION registry–
GWTG
TM
 registry, those at high risk of bleeding and mortality were less likely to receive 
Clopidogrel (70% vs. 51%), coronary angiography within 48 hours (86% vs. 41%) and 
revascularization (75% vs. 37%), compared with those at lowest risk of bleeding and 
mortality.[24] The observations in their analysis, justified as being due to physicians’ 
concerns about ‘attributable risk’, were consistent with our study findings.  















catheterisation in patients with a high risk (adjusted HR 0.45; 95% CI, 0.42-0.47; P<0.001) 
and intermediate GRACE score (adjusted HR 0.82; 95% CI, 0.77-0.86; P<0.001) compared 
to lower risk patients.[25] This analysis, however, only studied quality indictors based on 
ischemic risk, without taking bleeding risk in to account. Our findings underpin the gap in 
existing evidence on the optimal management strategy for dual high mortality- high bleeding 
risk patients and emphasizes the need for further prospective studies to inform cardiologists’ 
decision-making of this frequently encountered risk group.  
Current treatment strategies for this dual high-risk group are based on clinicians’ 
experience and involve the preferential use of clopidogrel over more potent P2Y12 inhibitors 
owing to its association with lower non-access related bleeding and the use of drug-coated 
(DCS) or bare metal stents (BMS) as opposed to drug eluting stents.[26, 27] However, a 
recent meta-analysis demonstrated no difference in bleeding events between Clopidogrel and 
newer P2Y12 inhibitors in both elderly and non-elderly patients.[28] Furthermore, there has 
been no head-to-head comparison of adverse cardiac events and bleeding between DES and 
DCS in this dual high-risk group to date.  
 
Limitations 
 There are several limitations to our study. Firstly, despite the high quality of the 
MINAP database, the retrospective nature of analysis is reliant on the accuracy of data 
entered by healthcare staff. Secondly, whilst mortality tracking within England is well 
structured and undertaken through the office of national statistics, all other clinical outcomes 
and post procedural complications are self-reported without official adjudication and are only 
captured during the in-hospital episode. Therefore, we were unable to report outcomes 
beyond the admission episode for adverse events other than mortality. Thirdly, whilst we 















registry, our data does not have measures of frailty and global comorbid burden that are 
known to influence outcomes in ACS patients and so our findings may relate to unmeasured 
confounders. Finally, our database was derived from three large interventional centres in the 




In our unselected cohort of patients admitted with an ACS, we demonstrate that 1 in 3 
patients are at high risk of both ischemic and bleeding events as defined by their GRACE and 
CRUSADE risk scores and represent a high-risk group with adverse clinical outcomes. These 
patients represent a diagnostic dilemma, since despite being at increased risk of both 
ischemic and bleeding events, they are less likely to receive guideline recommended 
therapies such as dual antiplatelet therapy or an invasive approach. Further work is required 
to identify patients in this high-risk group that would benefit from more aggressive 
management in line with international guidelines.   
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Figure 1. Key to study groups 
Figure 2a. In-hospital adverse events 
Figure 2b. 30-day mortality 



































 C G C G C G C G C G C G C G C G C G   
Age (years), mean (SD) 51.8 (9.6) 58.8 (9.3) 69.3 (11.4) 53.0 (9.6) 57.7 (10.0) 70.5 (11.9) 51.2 (9.7) 57.6 (9.8) 71.9 (11.9) 65.9 (13.1) <0.001 
Males, % 80.2 79.2 77.3 64.8 71.8 69.9 65.6 69.4 62.7 70.8 <0.001 
Caucasian, % 79.0 85.3 87.6 79.4 81.5 85.5 72.9 79.8 82.9 83.2 <0.001 
STEMI, % 24.6 51.8 57.0 25.0 45.1 54.1 28.7 50.7 53.1 50.8 <0.001 
Previous AMI, % 19.3 16.4 18.8 25.6 21.2 24.0 17.1 16.9 25.3 21.4 <0.001 
Previous angina, % 22.1 19.7 20.8 32.7 24.5 24.9 18.8 20.5 27.0 23.6 <0.001 
Previous PCI, % 15.2 11.9 10.5 21.9 15.1 12.2 13.6 11.6 12.3 12.3 0.001 
Previous CABG, % 3.4 3.6 5.1 3.8 5.6 6.0 2.9 4.6 6.7 5.4 <0.001 
Hypertension, % 44.9 45.5 52.0 51.4 46.6 56.4 45.3 47.1 62.7 54.0 <0.001 
Hypercholesterolaemia, % 41.3 38.5 39.1 52.2 44.0 41.8 38.5 42.5 41.2 40.9 <0.001 
Peripheral vascular 
disease, % 
1.3 2.0 1.8 3.6 5.2 4.9 5.9 4.6 8.6 4.9 <0.001 
Cerebrovascular disease, 
% 
2.8 4.3 6.5 2.9 4.4 8.7 2.6 5.0 10.8 7.3 <0.001 


































 C G C G C G C G C G C G C G C G C G   
Chronic renal failure, % 0.1 0.3 0.8 0.7 0.7 2.3 0.8 1.7 10.2 3.9 <0.001 
Heart Failure, % 0.6 1.0 2.0 1.9 1.1 3.0 1.3 1.5 6.1 3.1 <0.001 
Elevated Troponin, % 84.0 93.8 98.1 78.2 91.1 98.6 86.7 92.1 98.6 95.7 <0.001 
Previous/current smokers, 
% 
76.6 71.9 66.2 75.1 75.9 66.8 75.6 74.5 66.8 69.3 <0.001 
Diabetes  
Dietary control, % 2.3 2.1 2.2 5.2 3.0 3.1 3.1 4.1 5.2 3.5 <0.001 
Oral medicine, % 5.1 5.7 5.4 17.9 11.5 11.1 13.7 14.3 15.1 10.6 <0.001 
Insulin, % 2.1 1.5 1.3 7.1 4.2 3.0 3.8 5.1 8.1 4.3 <0.001 
Cholesterol (mmol/L), 
mean (SD) 
5.1 (1.4) 5 (1.3) 4.7 (1.3) 4.9 (1.4) 5 (1.3) 4.7(1.4) 5(1.2) 5(1.4) 4.5(1.3) 4.8 (1.4) <0.001 
Systolic BP (mmHg), mean 
(SD) 
143(22) 139 (23) 136 (27) 144 (25) 136 (25) 133(29) 144(22) 138(25) 131(31) 135 (28) <0.001 
Heart rate (bpm), mean 
(SD) 
70 (13) 72 (15) 73 (16) 71(16) 73 (17) 76 (19) 71(14) 75 (17) 82 (23) 76 (19) <0.001 


































 C G C G C G C G C G C G C G C G C G   
Creatinine (umol/L), mean 
(SD) 
72 (13) 75 (15) 82 (20) 74 (11) 80 (18) 93(27) 74 (15) 82(40) 126(101) 96 (64) <0.001 
Haemoglobin (g/L), mean 
(SD) 
144 (20) 142 (19) 137 (21) 139 (21) 141 (20) 133 (23) 141 (22) 139 (21) 129 (25) 135 (23) <0.001 
Admission under a 
Cardiologist, % 
99.4 99.5 98.4 99.1 99.6 97.5 97.8 98.9 95.0 97.5 <0.001 
Loop diuretics, % 3.4 5.2 14.6 7.9 7.5 21.7 3.7 10.3 35.5 19.4 <0.001 
Warfarin, % 2.3 3.7 5.1 2.1 2.6 6.2 1.3 2.9 7.8 5.4 <0.001 
Family history of CHD, % 65.5 57.1 48.4 65.6 61.5 50.1 61.1 54.9 44.6 51.4 <0.001 
Killip class, %  
I, % 96.3 91.7 73.4 92.2 83.9 62.0 94.0 82.7 45.9 68.5 <0.001 
II, % 3.6 7.2 17.0 7.5 14.8 22.7 5.6 15.7 29.8 19.3 <0.001 
III, % 0.1 0.7 5.9 0.3 1.0 9.1 0.4 1.3 14.4 7.3 <0.001 
IV, % 0.0 0.4 3.8 0.0 0.4 6.3 0.0 0.3 9.8 4.9 <0.001 
Cardiac arrest on 
admission, % 




































C G C G C G C G C G C G C G C G C G   
In-hospital NACE, % 1.1 1.2 3.1 1.0 2.0 5.9 1.2 2.3 10.9 5.5 <0.001 
In-hospital cardiac 
mortality, % 
0.1 0.2 1.1 0.4 0.7 3.3 0.1 0.6 7.9 3.3 <0.001 
In-hospital all-cause 
mortality, % 
0.1 0.2 1.2 0.4 0.8 3.9 0.1 0.6 8.8 3.9 <0.001 
30-day mortality, % 0.9 1.1 2.8 1.5 1.7 5.0 0.3 1.0 8.2 4.3 <0.001 
In-hospital re-
infarction, % 
0.5 0.4 1.1 0.1 1.1 1.2 0.4 0.9 1.8 1.2 <0.001 
In-hospital TIMI 
major bleeding, % 
0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.46 
In-hospital all-cause 
bleeding, % 
0.6 0.6 1.1 0.4 0.5 1.9 0.8 1.1 2.4 1.5 <0.001 
Receipt of coronary 
angiography, % 



































C G C G C G C G C G C G C G C G C G   
Beta-blockers on 
discharge, % 
98.4 97.8 97.1 97.5 97.5 96.6 95.6 97.1 95.3 96.6 <0.001 
ACEI on discharge, 
% 
94.7 96.4 95.5 95.2 96.6 94.3 91.4 92.4 91.6 93.9 <0.001 
Statin on discharge, 
% 
98.6 99.2 98.3 98.8 98.5 97.6 98.7 98.6 95.5 97.5 <0.001 
Aspirin only on 
discharge, % 
2.8 2.2 3.0 3.0 2.3 4.5 3.1 4.4 5.6 4.0 <0.001 
P2Y12 inhibitor only 
on discharge 
0.9 0.8 1.6 1.0 0.9 1.9 0.6 1.4 2.7 1.8 <0.001 
DAPT on discharge, 
% 
92.7 92.4 88.9 93.4 92.2 83.0 91.6 87.4 74.6 84.3 <0.001 



















aOR [95% Cl] p-value 
In-hospital NACE 
GROUP 1 (reference) C G  
GROUP 2 C G 0.70 [0.35, 1.39] 0.307 
GROUP 3 C G 1.85 [1.01, 3.39] 0.046 
GROUP 4 C G 0.94 [0.26, 3.37] 0.924 
GROUP 5 C G 1.26 [0.62, 2.57] 0.522 
GROUP 6 C G 3.23 [1.78, 5.85] <0.001 
GROUP 7 C G 0.78 [0.22, 2.78] 0.696 
GROUP 8 C G 1.56 [0.79, 3.07] 0.196 
GROUP 9 C G 6.33 [3.55, 11.29] <0.001 
In-hospital all-cause mortality 
GROUP 1 (reference) C G  
GROUP 2 C G 0.31 [0.08, 1.26] 0.101 
GROUP 3 C G 2.12 [0.76, 5.93] 0.154 
GROUP 4* C G 0.96 [0.11, 8.65] 0.971 
GROUP 5 C G 1.69 [0.53, 5.42] 0.377 
GROUP 6 C G 5.82 [2.13, 15.87] 0.001 
GROUP 7* C G 0.76 [0.09, 6.87] 0.809 
GROUP 8 C G 1.39 [0.43, 4.53] 0.587 
GROUP 9 C G 14.17 [5.27, 38.1] <0.001 
In-hospital all-cause bleeding 
GROUP 1 (reference) C G  
GROUP 2 C G 1.08 [0.38, 3.03] 0.888 
GROUP 3 C G 2.26 [0.88, 5.82] 0.091 















GROUP 5 C G 1.24 [0.38, 4.07] 0.726 
GROUP 6 C G 4.05 [1.60, 10.21] 0.001 
GROUP 7 C G 1.37 [0.26, 7.07] 0.711 
GROUP 8 C G 2.23 [0.78, 6.34] 0.134 
GROUP 9 C G 4.82 [1.96, 11.86] <0.001 
30-day mortality 
GROUP 1 (reference) C G  
GROUP 2 C G 1.67 [0.77, 3.64] 0.197 
GROUP 3 C G 3.79 [1.83, 7.84] <0.001 
GROUP 4* C G 2.87 [0.93, 8.87] 0.066 
GROUP 5 C G 2.54 [1.11, 5.82] 0.028 
GROUP 6 C G 6.93 [3.38, 14.2] <0.001 
GROUP 7* C G 0.45 [0.06, 3.61] 0.452 
GROUP 8 C G 1.02 [0.39, 2.66] 0.967 
GROUP 9 C G 10.79 [5.33, 21.81] <0.001 
Receipt of coronary angiography 
GROUP 1 (reference) C G   
GROUP 2 C G 0.61 [0.50, 0.74] <0.001 
GROUP 3 C G 0.39 [0.32, 0.47] <0.001 
GROUP 4 C G 1.04 [0.69, 1.58] 0.848 
GROUP 5 C G 0.62 [0.49, 0.78] <0.001 
GROUP 6 C G 0.38 [0.32, 0.46] <0.001 
GROUP 7 C G 0.68 [0.48, 0.95] 0.025 
GROUP 8 C G 0.39 [0.31, 0.48] <0.001 
GROUP 9 C G 0.24 [0.20, 0.29] <0.001 
Receipt of DAPT on discharge 
GROUP 1 (reference) C G   
GROUP 2 C G 0.97 [0.70, 1.32] 0.827 















GROUP 4 C G 1.04 [0.56, 1.93] 0.901 
GROUP 5 C G 0.92 [0.63, 1.34] 0.658 
GROUP 6 C G 0.42 [0.31, 0.55] <0.001 
GROUP 7 C G 0.91 [0.55, 1.52] 0.723 
GROUP 8 C G 0.56 [0.39, 0.80] 0.002 
GROUP 9 C G 0.26 [0.20, 0.34] <0.001 
aOR: adjusted odds ratio; CI: confidence interval; NACE: net adverse cardiac events; DAPT: dual  

















 Combined GRACE-CRUSADE risk assessment demonstrated that one in five patients 
with ACS are at high risk of future bleeding and ischemic events.  
 ‘Dual high-risk’ bleeding-ischemic groups are at greater risk of adverse outcomes and 
yet less likely to receive guideline-based therapy.  
 Further work is required to identify alternative management strategies that would 
improve the clinical outcomes of ‘dual high-risk’ patients.  
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